Paclitaxel (PTX) and docetaxel (DTX) are key members of taxenes with high anti-tumor activity against various cancer cells. These chemotherapeutic agents suffer from a number of drawbacks and it seems that low solubility in water is the most important one. Although much effort has been made in improving the bioavailability of PTX and DTX, the low bioavailability and minimal accumulation at tumor sites are still the challenges faced in PTX and DTX therapy.As a consequence, biomaterial-synthesized NPs have attracted much attention due to unique properties. Among them, chitosan (CS) is of interest due to its great biocompatibility. CS is a positively charged polysaccharide with the capability of interaction with negatively charged biomolecules. Besides, it can be processed into the sheet, micro/nano-particles, scaffold, and is dissolvable in mildly acidic pH similar to the pH of the tumor microenvironment. Keeping in mind the different applications of CS in the preparation of nanocarriers for delivery of PTX and DTX, in the present review, we demonstrate that how CS functionalized-nanocarriers and CS modification can be beneficial in enhancing the bioavailability of PTX and DTX, targeted delivery at tumor site, image-guided delivery and co-delivery with other anti-tumor drugs or genes.

Trigonelline (TRG) as a polar hydrophilic alkaloid is extracted from many plant species, for example, Trigonella foenum-graecum, Allium sepapea, Coffea sp, Pissum sativum, Glycine max, and Lycopersicon esculentum. Numerous biological activities have been reported for TRG such as protection of heart and liver and treatment of hyperglycemia, hypercholesterolemia, nervous and hormonal disorders, and cancers. Thus, the aim of this review is to summarize some information about TRG's biosynthesis pathway, pharmacological activity, pharmacokinetics, and analytical techniques to introduce TRG as an alternative choice to treat the various diseases. However, current evidence is still inadequate for introducing TRG as a novel drug, and it is necessary to examine more clinical trials to determine its acute and chronic side effects, bioavailability, pharmacokinetic parameters, and mechanisms of action.

No abstract

No abstract

The present study reports the synthesis of ZnO-NPs using Acantholimon serotinum extracts followed by characterization and evaluation of biological activities. Field emission scanning electron microscope revealed irregular spherical morphology with a size in the range of 20–80 nm. The X-ray diffraction analysis confirmed the synthesis of highly pure ZnO NPs with a hexagonal shape and a crystalline size of 16.3 nm. The UV-Vis spectroscopy indicates the synthesis of ZnO-NPs. FT-IR confirmed the presence of phytocomponents in the plant extract, which was responsible for nanoparticle synthesis. According to MTT results, the biosynthesized ZnO-NPs showed cytotoxic effects on human colon cancer Caco-2 (IC50: 61 µg/mL), neuroblastoma SH-SY5Y (IC50: 42 µg/mL), breast cancer MDA-MB-231 (IC50: 24 µg/mL), and embryonic kidney HEK-293 (IC50: 60 µg/mL) cell lines. Significant reactive oxygen species (ROS) generation was measured by the DCFH-DA assay after 24 h incubation with ZnO-NPs (200 µg/mL). ZnO-NPs caused apoptotic and necrotic effects on cells, which was confirmed by Annexin V-PE/7-AAD staining and 6.8-fold increase in pro-apoptosis gene Bax and 178-fold decrease in anti-apoptosis gene Bcl-2. The well diffusion method did not show effective growth inhibition activities of the ZnO-NPs against bacteria. In conclusion, the ZnO-NPs induce cytotoxicity in cell lines through ROS generation and oxidative stress.